These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 2297763

  • 21. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS, Mangalik A, Ferguson J, Elias L.
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [Abstract] [Full Text] [Related]

  • 22. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [Abstract] [Full Text] [Related]

  • 23. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 24. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
    Ward FT, Kelley JA, Roth JS, Lombardo FA, Weiss RB, Leyland-Jones B, Chun HG.
    Cancer Res; 1991 Apr 01; 51(7):1803-10. PubMed ID: 2004365
    [Abstract] [Full Text] [Related]

  • 25. Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
    Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T.
    Clin Cancer Res; 1999 Jul 01; 5(7):1723-30. PubMed ID: 10430075
    [Abstract] [Full Text] [Related]

  • 26. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, Cherny RC, Wright J, Behr J, Snow C, Schacter LP.
    Bone Marrow Transplant; 1996 Nov 01; 18(5):851-6. PubMed ID: 8932836
    [Abstract] [Full Text] [Related]

  • 27. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH.
    Clin Cancer Res; 1997 Jan 01; 3(1):39-46. PubMed ID: 9815535
    [Abstract] [Full Text] [Related]

  • 28. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ.
    Clin Cancer Res; 2002 Aug 01; 8(8):2524-9. PubMed ID: 12171879
    [Abstract] [Full Text] [Related]

  • 29. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M.
    Cancer Res; 1991 Feb 01; 51(3):935-8. PubMed ID: 1988134
    [Abstract] [Full Text] [Related]

  • 30. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
    Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM.
    Clin Cancer Res; 1998 Feb 01; 4(2):357-60. PubMed ID: 9516923
    [Abstract] [Full Text] [Related]

  • 31. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovren JP, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1998 Nov 01; 4(11):2763-70. PubMed ID: 9829740
    [Abstract] [Full Text] [Related]

  • 32. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L.
    Clin Cancer Res; 1995 Dec 01; 1(12):1487-93. PubMed ID: 9815948
    [Abstract] [Full Text] [Related]

  • 33. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM.
    Clin Cancer Res; 1999 Mar 01; 5(3):525-31. PubMed ID: 10100703
    [Abstract] [Full Text] [Related]

  • 34. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.
    Cancer; 2006 Sep 15; 107(6):1383-90. PubMed ID: 16902987
    [Abstract] [Full Text] [Related]

  • 35. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.
    Clin Cancer Res; 1997 May 15; 3(5):755-60. PubMed ID: 9815746
    [Abstract] [Full Text] [Related]

  • 36. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 2002 Jul 15; 8(7):2157-66. PubMed ID: 12114416
    [Abstract] [Full Text] [Related]

  • 37. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
    Hainsworth JD, Raefsky EL, Greco FA.
    Cancer J Sci Am; 1995 Jul 15; 1(4):281-7. PubMed ID: 9166489
    [Abstract] [Full Text] [Related]

  • 38. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA, McCormack JJ, Tong W, Low JB, Roberts JD, Blow A, Whitfield LR, Haugh LD, Grove WR, Lopez AJ.
    Cancer Res; 1988 Sep 01; 48(17):5029-35. PubMed ID: 2970294
    [Abstract] [Full Text] [Related]

  • 39. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F.
    Cancer Res; 1989 Oct 01; 49(19):5475-9. PubMed ID: 2670205
    [Abstract] [Full Text] [Related]

  • 40. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
    Schilcher RB, Haas CD, Samson MK, Young JD, Baker LH.
    Cancer Res; 1986 Jun 01; 46(6):3147-51. PubMed ID: 3698029
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.